Related Experiment Video
Updated: Jan 14, 2026

Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
Protective effects of Polygonum cuspidatum bioactive constituents against cholestatic liver injury: A mechanistic
Zengni Zhang1, Xiao Yang2, Yan Fu1
1School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, China.
Ethnopharmacological Relevance:
Polygonum cuspidatum Sieb. et Zucc. has long been prescribed in Traditional Chinese Medicine for jaundice, hepatitis, and cholestasis. Its major stilbenes (polydatin, resveratrol) and anthraquinones (emodin, quercetin) exhibit clinically relevant hepatoprotective effects.
Aim Of The Review:
To systematically summarize mechanistic evidence for P. cuspidatum and its bioactive constituents in experimental models of cholestatic liver injury (CLI) and to evaluate their translational potential.
Materials And Methods:
Literature was retrieved from PubMed, Web of Science, Scopus, and CNKI through June 2025. Data on pharmacodynamics, signaling pathways, and efficacy endpoints were extracted and synthesized.
Results:
Polydatin, resveratrol, emodin, and quercetin alleviate CLI by regulating bile-acid synthesis and transport via the farnesoid X receptor (FXR), pregnane X receptor (PXR), and bile salt export pump (BSEP); activating Nrf2-dependent antioxidant defenses; suppressing NF-κB-mediated inflammation; and inhibiting TGF-β-driven fibrogenesis. Multi-target effects were confirmed in α-naphthylisothiocyanate(ANIT), bile-duct-ligation, and genetic cholestasis models with dose-dependent biochemical and histological improvements.
Conclusions:
P. cuspidatum offers a multi-pathway therapeutic strategy for CLI. Rigorous clinical trials are warranted to define optimal dosing, safety profile, and efficacy in patients.
Related Concept Videos
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...

